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physician. Over 1.7 million inpatient records are used in the analysis. RESULTS: 
Our risk-adjusted results show that medical litigation against physicians 
increase the average cost of inpatient hospital visits about 11%. We find that 
hospital inpatient costs registered to surgeons with no medical litigation history 
is higher (about 28%) at hospitals where there is at least one surgeon facing 
medical litigations when compared to the hospitals where there is no surgeon 
associated with medical litigation history. The magnitude of spillover effects are 
in between 2 percent and 28% for other physician specialties except for 
obstetricians and/or gynecologists for whom we found no spillover effects. 
CONCLUSIONS: Medical litigation against physicians increases the hospital 
inpatient costs. There is significant variation in spillover effects of medical 
litigations across major board certified physician groups.  
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OBJECTIVES: The influence of financial status on life satisfaction is well 
discussed among economists. In contrast, population surveys indicate that 
general health is viewed by most subjects as key contributor to life satisfaction. 
We therefore aimed at analyzing the reciprocal impacts of morbidity and 
economic status on life satisfaction as a health outcome variable. METHODS: In 
2007, two representative adult samples of the Kantar Health European 
Healthcare Panel in Germany and UK were surveyed (n=72.605) and self-reports 
on 22 chronic diseases (12-month-prevalences summed up to a multimorbidity 
score) and household income (net household income in GBP) were collected. In 
2012, a subsample of 4.008 individuals was re-contacted and participants 
completed a health status and a validated life satisfaction questionnaire (IZA 
LSQ) with five domains: Life as a whole, work, social contacts, income and health 
(Kapteyn et al. 2008). The five-year impact of multimorbidity and income on life 
satisfaction was estimated using a stepwise multiple linear regression model, 
considering age and gender as confounders. RESULTS: Multimorbidity and 
income were moderately but significantly correlated with general life 
satisfaction (linear regression beta-coefficients: beta=0.26 resp. 0.25; p<0.01). 
Correlations with the outcome categories satisfaction with work, social contacts, 
income and health were also positive (beta coefficients between 0.15 and 0.40; all 
p<0.01). All effects were independent of age and gender. As expected, disease 
status had the greatest influence on satisfaction with health (beta=0.40) but also 
on satisfaction with work and functional capacity (beta=0.25). CONCLUSIONS: 
The results demonstrate specific, independent but complementary impacts of 
health status and income on life satisfaction and its domains. The impact on 
societal resource allocation decisions is being discussed: Optimal population 
based life satisfaction might require combining health care and economic 
improvements.  
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OBJECTIVES: One of the key drivers behind the UK’s health service reforms has 
been to reduce regional and local variability of access to care and medicines. 
However, the devolved countries in the UK also have individual challenges- 
recently the Scottish Health Secretary, Alex Neil, said a review of the Scottish 
Medicines Consortium (SMC) was launched in response to “concerns about 
variable access to medicines” raised by some clinicians, charities and patients. 
This study interviewed NHS leaders in Scotland to understand the reasons 
behind this variable uptake of SMC guidance. METHODS: Secondary research to 
understand NHS drivers & local decision-making processes followed by 
1:1stakeholder interviews with 12 NHS Senior payers across Scotland. RESULTS: 
Scotland’s NHS is renowned as being at the forefront of new technologies and 
innovation. Uptake of guidance, like that of NICE is mandated, however, Health 
Boards (HBs) are facing many challenges to balance the national quality agenda 
with a need to make tough efficiency savings to ensure HBs continue to deliver 
for the local population. Whilst national groups such as NICE and SMC are seen 
as leaders within the HTA space, it would appear that a huge challenge within 
countries adopting these HTA recommendations and guidance will continue to 
be equitable implementation across the country, however this will now be 
greatly influenced by local decisions on affordability, similar to the decentralized 
picture in Italy and Spain. CONCLUSIONS: The implementation of SMC guidance 
was seen as a national driver by Scottish Health Boards (HBs). Implementation 
decisions are taken at a HB level and a key driver influencing implementation is 
now local affordability and infrastructure capacity, of interest for many payers is 
the challenge of medicines optimization  
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OBJECTIVES: To evaluate the consistency of information given in drug brochures 
by pharmaceutical companies METHODS: Total of 500 drug brochures were 
collected from the doctors’ clinics in Pakistan and 473 brochures were collected 
from the general practitioners’ clinics in Malaysia. After comprehensive scrutiny, 
a total of 498 brochures were included and evaluated for the study. An 
evaluation form was developed based on the criteria given by WHO, FIPMA, 
DCOMOH(Pakistan) and PhAMA. The data was analyzed using SPSS. To 
summarize the data, descriptive statistics (frequencies, percentages,) were 
calculated and Chi-square test and Fisher’s exact test were applied as inferential 
statistics. A Pvalue of less than 0.05 was considered as statistical significance for 
all the tests. RESULTS: The Cronbach’s coefficient Alpha value was 0.729 (n=50). 
The study found that the dosage form was presented significantly (P=0.009) less 
in national companies’ (NCs) brochures as compared to MNCs. MNCs were found 
significantly adherent to the standard criteria for brochures as compared to NCs 
for presenting drug interactions (P<0.001), precautions (P<0.001) and expected 
ADRs (P<0.001). National companies were found significantly (P<0.001) adherent 
to the standard criteria in terms of presenting contraindications and warnings. 
MNCs were significantly better (P=0.009) in terms of including contact 
information in the brochures. A significantly higher number of Malaysian 
brochures providing information about drug interactions (P<0.001), precautions 
(P<.001), expected ADRs (P<0.001) and contraindications (P<0.001). On average 3 
(median, IQR=5) references were used in the brochures out of which on average 2 
(median, IQR=6) references were understandable. The references having enough 
information to access particular study were considered understandable. 
CONCLUSIONS: The drug information given in the brochures, discrepancies are 
observed mainly in drug safety related information like side effects, possible 
ADRs, precautions etc. The references cited in the brochures were also found to 
be inappropriate and incomplete.  
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OBJECTIVES: Death after complication, or “Failure to Rescue” (FTR), contributes 
to differences in risk-adjusted mortality rates among trauma centers and is 
considered an indicator of quality of care. The objective of our study was to 
assess the effect of specific comorbidities on FTR outcomes in trauma patients. 
METHODS: We performed a retrospective cohort study that analyzed patient 
records included in the National Trauma Data Bank (NTDB) from years 2008-
2010. The dataset was limited to patients with an injury severity score greater 
than 9 and who were between the ages of 18 and 64. Only patients treated at 
hospitals with adequate complication reporting were included in the analysis. 
Cox regression modeling was used to determine the contribution of individual 
comorbidities to FTR outcomes while controlling for injury severity, head  
injury, mechanism of injury, hypotension, age, gender, race, and insurance  
type. RESULTS: Diabetes, congestive heart failure, history of myocardial 
infarction, and dialysis were associated with greater hazard ratios for FTR [HR 
1.18 (CL 1.05, 1.32), 1.45 (1.16, 1.81), 1.30 (1.01, 1.67), 2.02 (1.50, 2.72), respectively]. 
Obesity and hypertension were not with associated with increased risk of  
FTR. CONCLUSIONS: Pre-existing comorbidities contributed significantly to  
risk of death after complication in the trauma population. Identifying  
processes of care that lead to better management of complications in  
patients with comorbidities would improve trauma centers' overall mortality 
outcomes.  
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OBJECTIVES: This study aims to explore safety culture dimensions among health 
care professionals using AHRQ (Agency for Healthcare Research and Quality)’s 
survey questionnaire(Hospital Survey of patient Safety Culture: HSOPSC). 
METHODS: We surveyed nationwide the situation of patient safety culture in 13 
hospitals allowed for additional costs on patient safety measures under the 
social insurance medical fee schedule. The questionnaire consists of seven unit-
level aspects of safety culture including 24 items, three hospital-level including 
11 items, and four outcome variables including nine items. RESULTS: An average 
number of beds was 360 beds (63 to 1,354 beds). With regard to ownership, 13 
hospitals included three municipality and local incorporated agency hospitals, 
one public hospital, two juridical person with social insurance hospitals, six 
medical corporation hospitals, and one other hospital. Number of all 
respondents was 5,118 persons (response rate: 88.9%), and included 295 
physicians (90.8%), 2,909 nurses (95.5%), and 146 pharmacists (96.7%). In terms of 
12 dimensions, the overall average positive response rate (RR) for the 12 patient 
safety dimensions of the HSOPS was 49.2%, extremely lower than the average 
positive RR for the AHRQ data (61%). In terms of health care professionals, the 
overall average positive RR for pharmacists (46.2%) was lower than that for 
physicians and nurses (49.6% and 49.4%). With regard to pharmacists, the 
average positive RRs for eight dimensions of the 12 dimensions were the lowest 
among three professionals, and three average positive RRs were the highest; 
Frequency of event reporting (pharmacists: physicians: 
nurses=73.6%:53.3%:67.9%), Non-punitive response to error (48.8%:42.6%:40.4%), 
and Staffing (29.1%:27.0%:25.4%). CONCLUSIONS: The HSOPSC measurement 
provides the evidence for assessment of patient safety culture in Japan’s 
hospitals. This result that patient safety culture has been in a state of 
development, compared with the US hospitals. And, pharmacists have to take a 
considerable interest patient safety in Japan.  
